BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46:711-721. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
2 Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421-431. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
3 Chhatwal J, Chen Q, Bethea ED, Ladd MA, Mueller PP, Hutin Y, Aggarwal R. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. The Lancet Gastroenterology & Hepatology 2018;3:819. [DOI: 10.1016/s2468-1253(18)30281-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
4 Lai JC, Ho AH, Wu CW, Wong GL. HCV elimination in Hong Kong - Non-government organisation (NGO) activities. Glob Health Med 2021;3:283-7. [PMID: 34782870 DOI: 10.35772/ghm.2021.01049] [Reference Citation Analysis]
5 Chhatwal J, Chen Q, Ayer T, Bethea ED, Kanwal F, Kowdley KV, Wang X, Roberts MS, Gordon SC. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Aliment Pharmacol Ther 2018;47:1023-31. [PMID: 29377245 DOI: 10.1111/apt.14527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
6 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 He YL, Yang SJ, Hu CH, Dong J, Gao H, Yan TT, Liu JF, Yang Y, Ren DF, Zhu L, Zhao YR, Chen TY. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther 2018;47:526-32. [DOI: 10.1111/apt.14429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, Sharma RK, Rai P, Aggarwal R. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton) 2019;24:316-21. [PMID: 29327401 DOI: 10.1111/nep.13222] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
9 Chen S, Guo L, Wang Z, Mao W, Ge Y, Ying X, Fang J, Long Q, Liu Q, Xiang H, Wu C, Fu C, Dong D, Zhang J, Sun J, Tian L, Wang L, Zhou M, Zhang M, Qian M, Liu W, Jiang W, Feng W, Zeng X, Ding X, Lei X, Tolhurst R, Xu L, Wang H, Ziegeweid F, Glenn S, Ji JS, Story M, Yamey G, Tang S. Current situation and progress toward the 2030 health-related Sustainable Development Goals in China: A systematic analysis. PLoS Med 2019;16:e1002975. [PMID: 31743352 DOI: 10.1371/journal.pmed.1002975] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
10 Jena AB, Snider JT, Diaz Espinosa O, Ingram A, Sanchez Gonzalez Y, Lakdawalla D. How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom? Value Health 2019;22:669-76. [PMID: 31198184 DOI: 10.1016/j.jval.2018.09.2923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
11 van Boemmel-Wegmann S, Lo Re V 3rd, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020;65:3159-74. [PMID: 31938995 DOI: 10.1007/s10620-019-06037-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wei X, Zhao J, Yang L. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Glob Health 2020;5:e003194. [PMID: 33246983 DOI: 10.1136/bmjgh-2020-003194] [Reference Citation Analysis]
13 Connoley D, Francis-Graham S, Storer M, Ekeke N, Smith C, Macdonald D, Rosenberg W. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison. J Viral Hepat. 2020;27:987-995. [PMID: 32449969 DOI: 10.1111/jvh.13336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res 2019;5:31. [PMID: 31453368 DOI: 10.20517/2394-5079.2019.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
15 Nguyen HA, Cooke GS, Day JN, Flower B, Phuong LT, Hung TM, Dung NT, Khoa DB, Hung LM, Kestelyn E, Thwaites GE, Chau NVV, Turner HC; SEARCH Investigators. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. Wellcome Open Res 2019;4:129. [PMID: 32734002 DOI: 10.12688/wellcomeopenres.15408.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lopez-Tejedor D, Claveria-Gimeno R, Velazquez-Campoy A, Abian O, Palomo JM. In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus. Pharmaceuticals (Basel) 2021;14:759. [PMID: 34451856 DOI: 10.3390/ph14080759] [Reference Citation Analysis]
17 Luo A, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore) 2019;98:e15626. [PMID: 31096473 DOI: 10.1097/MD.0000000000015626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
18 Due OT, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value Health. 2020;23:1180-1190. [PMID: 32940236 DOI: 10.1016/j.jval.2020.03.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L, Zahid H, Van den Bergh R, Falq G, Fortas C, Wailly Y, Auat R, Donchuk D, Loarec A, Coast J, Vickerman P, Walker JG. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan. J Viral Hepat 2021;28:268-78. [PMID: 33051950 DOI: 10.1111/jvh.13422] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018;25 Suppl 1:6-17. [PMID: 29508946 DOI: 10.1111/jvh.12875] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
21 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus. Intern Med 2020;59:2653-60. [PMID: 33132304 DOI: 10.2169/internalmedicine.5102-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ioannou GN, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology. 2019;156:446-460.e2. [PMID: 30367836 DOI: 10.1053/j.gastro.2018.10.033] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
23 Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health 2019;19:39. [PMID: 30621662 DOI: 10.1186/s12889-018-6347-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
24 Wong WW, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Feng Z, Feld JJ, Mitsakakis N, Powis J, Krahn M. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 2022;25:247-56. [DOI: 10.1016/j.jval.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open 2018;8:e021443. [PMID: 30552244 DOI: 10.1136/bmjopen-2017-021443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rodríguez-Osorio I, Mena A, Meijide H, Morano L, Delgado M, Cid P, Margusino L, Pedreira JD, Castro Á. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One 2019;14:e0217052. [PMID: 31158237 DOI: 10.1371/journal.pone.0217052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Spaulding AC, Adee MG, Lawrence RT, Chhatwal J, von Oehsen W. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination. Infect Dis Clin North Am 2018;32:323-45. [PMID: 29778259 DOI: 10.1016/j.idc.2018.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
29 Wong GL, Chan HL, Loo C, Hui Y, Fung JY, Cheung D, Chung C, Chim AM, Wong VW; On behalf of the Hong Kong Association for the Study of Liver Diseases (HKASLD). Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct‐acting antiviral therapy. Journal of Gastroenterology and Hepatology 2019;34:1641-7. [DOI: 10.1111/jgh.14622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
30 Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA, Thakkinstian A. Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries. Open Forum Infect Dis 2019;6:ofz117. [PMID: 31049363 DOI: 10.1093/ofid/ofz117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
31 Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol 2019; 25(11): 1327-1340 [PMID: 30918426 DOI: 10.3748/wjg.v25.i11.1327] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
32 Axelrod DA, Schnitzler MA, Alhamad T, Gordon F, Bloom RD, Hess GP, Xiao H, Nazzal M, Segev DL, Dharnidharka VR, Naik AS, Lam NN, Ouseph R, Kasiske BL, Durand CM, Lentine KL. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes. Am J Transplant 2018;18:2473-82. [PMID: 29701909 DOI: 10.1111/ajt.14895] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
33 Puig-Junoy J, Pascual-Argente N, Puig-Codina L, Planellas L, Solozabal M. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:1251-63. [PMID: 30791790 DOI: 10.1080/17474124.2018.1540929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
34 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
35 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Behzadifar M, Gorji HA, Rezapour A, Behzadifar M, Bragazzi NL. The role of insurance providers in supporting treatment and management of hepatitis C patients. BMC Health Serv Res 2019;19:25. [PMID: 30630488 DOI: 10.1186/s12913-019-3869-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]